Wendy Stock to Sirolimus
This is a "connection" page, showing publications Wendy Stock has written about Sirolimus.
Connection Strength
0.071
-
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 01; 14(9):2756-62.
Score: 0.071
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.